Protective effects of citicoline-containing eye drops against UVB-Induced corneal oxidative damage in a rat model

Tokuç, Ecem Önder; Yüksel, Nurşen; Rençber, Selenay Furat; Ozturk, Ahmet; Duruksu, Gökhan; Yazır, Yusufhan; Ergün, Riza Emre

doi:10.1016/j.exer.2021.108612

Cited by 13 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Citicoline treatment may be effective in suppressing oxidative stress and consequently controlling inflammation in UVB corneal injury. Citicoline exerts this effect by inhibiting lipid peroxidation and increasing antioxidant defense mechanisms (Tokuc et al, 2021).…”

Section: Some Additional Notes Involving the Mechanism Of The Describ...mentioning

confidence: 99%

Pharmacological Versus Non-Pharmacological and Ancillary Mechanisms in Eye Drops Used in the Treatment of Glaucoma

Marchesi

Fahmideh²,

Barbieri³

et al. 2022

Front. Drug Saf. Regul.

View full text Add to dashboard Cite

Medical Devices Made of Substances (MDMS) are increasingly used in the healthcare system alongside classic medicinal products and constitute an important field of experimentation and innovation in the biomedical field. In fact, these products are rapidly establishing themselves as a valuable therapeutic resource and are available in various forms including, but not limited to, creams, syrups, nasal or oropharyngeal sprays, and eye drops. MDMS are marketed to treat different diseases and the advantages and benefits of the use of these products can be claimed, once proven their clinical activity. What are the differences between medicinal products and MDMS? The substantial difference lies in the mechanism of action: the first case is based on pharmacological, metabolic, and immunological actions while the second one is based on mechanical, or chemical/physical action. Sometimes the boundaries are not well defined and there is a need for a reassessment and a consensus on the underlying concepts and definitions, also in the light of the increasing ability to recognize molecular mechanisms underneath the action of several substances not acting through an easy recognizable unique target (as a receptor, for example). In the present paper, we discuss the role of eye drops as an example of MDMS used in glaucoma, a widely diffused eye disease. The choice is due to the fact that some products used in this field of application and containing similar substances are marketed either as medicinal products or as medical devices or, using other dosage forms, as food supplements. Accordingly, it is important to underscore in the various cases what may be the principal mode of action and the contribution of additional mechanisms as derived, for example, from system pharmacology data. Their analysis may help to exemplify some of the problems around the sometimes fuzzy border between MDMS and medicinal products suggesting the need for new definitions and regulatory decisions about MDMS.

show abstract

Section: Some Additional Notes Involving the Mechanism Of The Describ...mentioning

confidence: 99%

Pharmacological Versus Non-Pharmacological and Ancillary Mechanisms in Eye Drops Used in the Treatment of Glaucoma

Marchesi

Fahmideh²,

Barbieri³

et al. 2022

Front. Drug Saf. Regul.

View full text Add to dashboard Cite

show abstract

“…Now there are citicoline in eye drops formulations for the management of glaucoma [ 818 - 821 ]. Tokuc et al [ 822 ] demonstrate the protective effects of citicoline eye drops on ultraviolet B radiation-induced corneal oxidative damage in a rat model. Parisi et al [ 823 ] reported the results of a pilot study evaluating the long-term efficacy of citicoline and vitamin B 12 eye drops on macular function in patients with type 1 diabetes with mild signs of non-proliferative diabetic retinopathy.…”

Section: Clinical Experiencementioning

confidence: 99%

“…Ahora hay citicolina en formulaciones de gotas para los ojos para el manejo del glaucoma [ 818 - 821 ]. Tokuc et al [ 822 ] demuestran los efectos protectores de las gotas oftálmicas de citicolina sobre el daño oxidativo corneal inducido por la radiación ultravioleta B en un modelo de rata. Parisi et al [ 823 ] comunicaron los resultados de un estudio piloto que evaluó la eficacia a largo plazo de los colirios de citicolina y vitamina B 12 sobre la función macular en pacientes con diabetes de tipo 1 con signos leves de retinopatía diabética no proliferativa.…”

Section: Experiencia Clínicaunclassified

Citicolina: revisión farmacológica y clínica, actualización 2022

Ruiz¹,

Gareri²

2022

RevNeurol

View full text Add to dashboard Cite

Resumen Esta revisión se basa en la publicada en 2016 –Secades JJ. Citicolina: revisión farmacológica y clínica, actualización 2016. Rev Neurol 2016; 63 (Supl 3): S1-S73–, e incorpora 176 nuevas referencias aparecidas desde entonces, con toda la información disponible para facilitar el acceso a toda la información en un único documento. La revisión se centra en las principales indicaciones del fármaco, como los accidentes cerebrovasculares agudos y sus secuelas, incluyendo el deterioro cognitivo, y los traumatismos craneoencefálicos y sus secuelas. Se recogen los principales aspectos experimentales y clínicos en estas indicaciones.

show abstract

“…Compared with ultraviolet A which can directly reach the retina, ultraviolet radiation at a shorter wavelength, designated as ultraviolet B (UVB, wavelength between 280 and 320 nm), is found to cause severe and long-term injury to the cornea, leading to complications such as opacification, edema, or photokeratitis [ 5 , 6 ]. One of the causes of ocular damage induced by UVB is the generation of reactive oxygen species (ROS)/reactive nitrogen species (RNS) and the decrease of corneal antioxidants [ [7] , [8] , [9] ]. Such a prooxidant/antioxidant imbalance may result in the oxidative injury of the cornea and further causes the damage to cellular lipids, proteins, or DNAs, and eventually leads to cell apoptosis [ 5 , 10 ].…”

Section: Introductionmentioning

confidence: 99%